New angiotensins

Journal of Molecular Medicine

Volumn 86, Issue 6, 2008, Pages 663-671

  Varagic, Jasmina ^a   Trask, Aaron J ^a   Jessup, Jewell A ^a   Chappell, Mark C ^a   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

(3 6): Renin angiotensin system; Angiotensin (1 12); Angiotensin (1 7); Cardiovascular growth; Hypertension; Novel angiotensins

Indexed keywords

AMINO ACID; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-12]; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; OMAPATRILAT;

CARDIOVASCULAR FUNCTION; CHEMICAL ANALYSIS; DRUG MECHANISM; GENE FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PREGNANCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RODENT;

ANGIOTENSINS; ANIMALS; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 43449113848     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-008-0340-4     Document Type: Review

References (110)

1. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI (1997) Counterregulatory actions of angiotensin-(1-7). Hypertension 30:535-541
2. Ferrario CM (1998) Angiotensin-(1-7) and antihypertensive mechanisms. J Nephrology 11:278-283
3. Ferrario CM, Iyer SN (1998) Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. Regul Pept 78:13-18
4. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Diz DI, Gallagher PE, Tallant EA (2004) Angiotensin-(1-7). Its contributions to arterial pressure control mechanisms. In: Unger T, Scholkens BA (eds) Handbook of experimental pharmacology: angiotensin, vol. 1. Heidelberg, Germany, pp 478-518
5. Ferrario CM, Trask AJ, Jessup JA (2005) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol 289:H2281-H2290
6. Ferrario CM (2006) Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 47:515-521
7. Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM (1994) Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4.24.15) in vascular smooth muscle cells. J Vasc Med Biol 5:129-137
8. Welches WR, Santos RAS, Chappell MC, Brosnihan KB, Greene LJ, Ferrario CM (1991) Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertens 9:631-638
9. Welches WR, Brosnihan KB, Ferrario CM (1993) A comparison of the properties, and enzymatic activity of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 52:1461-1480
10. Santos RAS, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM (1992) Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 19(Suppl II):II-56-II-61
11. Turner AJ (2003) Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem Soc Trans 31:723-727
12. Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA (1998) Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther 287:567-577
13. Chappell MC, Gomez MN, Pirro NT, Ferrario CM (2000) Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. Hypertension 35:348-352
14. Iyer SN, Ferrario CM, Chappell MC (1998) Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31:356-361
15. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR (1995) Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 13:797-804
16. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383:45-51
17. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277:14838-14843
18. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santo AJ, da Costa J, Zhang L, Pei Y, Scholey J, Bray MR, Ferrario CM, Backx PH, Manoukian AS, Chappell MC, Yagil Y, Penninger JM (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417:822-828
19. Huentelman MJ, Grobe J, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK (2005) Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90:783-790
20. Trask AJ, Averill DB, Ganten D, Chappell MC, Ferrario CM (2007) Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol 292:H3019-H3024
21. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC (2003) Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 108:1707-1712
22. Averill DB, Jessup JA, Ishiyama Y, Ferrario CM (2005) Augmented ACE2 expression in ischemic cardiomyopathy. Am J Hypertens 18:118A-118A
23. Allred AJ, Diz DI, Ferrario CM, Chappell MC (2000) Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am J Physiol 279:F841-F850
24. Chappell MC, Pirro NT, Sykes A, Ferrario CM (1998) Metabolism of angiotensin-(1-7) by angiotensin converting enzyme. Hypertension 31:362-367
25. Deddish PA, Jackman HL, Wang H-Z, Skidgel RA, Erdos EG (1997) An N-domain specific substrate and C-domain specific inhibitor of angiotensin converting enzyme: angiotensin-(1-7) and Keto-ACE. Hypertension 31:912-917
26. Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM (1998) Converting enzyme determines the plasma clearance of angiotensin-(1-7). Hypertension 98:496-502
27. Chappell MC, Allred AJ, Ferrario CM (2001) Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol Dial Transplant 16:22-26
28. Ferrario CM, Smith RD, Brosnihan KB, Chappell MC, Campese VM, Vesterqvist O, Liao W, Ruddy MC, Grim CE (2002) Effects of omapatrilat on the renin angiotensin system in salt sensitive hypertension. Am J Hyperten 15:557-564
29. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH, Diz DI (2002) Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Kid Int 62:1349-1357
30. Santos RAS, Campagnole-Santos MJ, Baracho NCV, Fontes MAP, Silva LCS, Neves LAA, Oliveira DR, Caligiorne SM, Rodrigues ARV, Gropen C Jr., Carvalho WS, Silva ACSE, Khosla MC (1994) Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin -(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 35:293-398
31. Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM (1997) Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension 29:388-392
32. Heitsch H, Brovkovych S, Malinski T, Wiemer G (2001) Angiotensin-(1-7)- stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 37:72-76
33. Brosnihan KB, Li P, Ferrario CM (1996) Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27:523-528
34. Porsti I, Bara AT, Busse R, Hecker M (1994) Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 111:652-654
35. Santos RAS, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Bul I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss H-P, Speth R, Walther T (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100:8258-8263
36. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP (2005) Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 46:937-942
37. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47:996-1002
38. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM (2007) Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49:185-192
39. Tallant EA, Ferrario CM, Gallagher PE (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol 289:H1560-H1566
40. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP (2006) Effects of genetic deletion of angiotensin-(1-7) receptor Mas on cardiac function during ischemia/reperfusion in the isolated perfused mouse heart. Life Sci 80:264-268
41. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA, Lemos VS (2007) Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 28:702-707
42. Canals M, Jenkins L, Kellett E, Milligan G (2006) Up-regulation of the angiotensin II type 1 receptor by the MAS proto-oncogene is due to constitutive activation of Gq/G11 by MAS. J Biol Chem 281:16757-16767
43. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T (2005) G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111:1806-1813
44. Schiavone MT, Santos RAS, Brosnihan KB, Khosla MC, Ferrario CM (1988) Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci USA 85:4095-4098
45. Ren Y, Garvin JL, Carretero OA (2002) Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39:799-802
46. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM (1998) Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31:699-705
47. Iyer SN, Averill DB, Chappell MC, Yamada K, Jones AG, Ferrario CM (2000) Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension 36:417-422
48. Iyer SN, Yamada K, Diz DI, Ferrario CM, Chappell MC (2000) Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. J Cardiovasc Pharmacol 36:109-117
49. Li P, Chappell MC, Ferrario CM, Brosnihan KB (1997) Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29:394-400
50. Moriguchi A, Tallant EA, Matsumura K, Reilly TM, Walton H, Ganten D, Ferrario CM (1995) Opposing actions of Angiotensin-(1-7) and Angiotensin II in the brain of transgenic hypertensive rats. Hypertension 25:1260-1265
51. Nakamoto H, Ferrario CM, Fuller SB, Robaczwski DL, Winicov E, Dean RH (1995) Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 25:796-802
52. Neves LA, Averill DB, Ferrario CM, Chappell MC, Aschner JL, Walkup MP, Brosnihan KB (2003) Characterization of angiotensin-(1-7) receptor subtype in mesenteric arteries. Peptides 24:455-462
53. Paula RD, Lima CV, Khosla MC, Santos RA (1995) Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 26:1154-1159
54. Greco AJ, Master RG, Fokin A Jr., Baber SR, Kadowitz PJ (2006) Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I. Can J Physiol Pharmacol 84:1163-1175
55. Carvalho MB, Duarte FV, Faria-Silva R, Fauler B, da Mata Machado LT, de Paula RD, Campagnole-Santos MJ, Santos RA (2007) Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension 50:762-767
56. Fernandes L, Fortes ZB, Nigro D, Tostes RC, Santos RA, Carvalho MHC (2001) Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension 37:703-709
57. Gorelik G, Carbini LA, Scicli AG (1998) Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 286:403-410
58. Oliveira MA, Fortes ZB, Santos RA, Kosla MC, De CM (1999) Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides 20:1195-1201
59. Tom B, de VR, Saxena PR, Danser AH (2001) Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 38:95-99
60. Ferrario CM, Jessup JA, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin converting enzyme 2. Circulation 111:2605-2610
61. Ferrario CM, Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Smith RD, Chappell MC (2005) Effects of renin angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68:2189-2196
62. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM (2006) Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol 291:H2166-H2172
63. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM (1996) Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 14:799-805
64. Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M (1998) Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 11:137-146
65. Schindler C, Brosnihan KB, Ferrario CM, Bramlage P, Maywald U, Koch R, Oertel R, Kirch W (2007) Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol 47:112-120
66. Schindler C, Bramlage P, Kirch W, Ferrario CM (2007) Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 3:125-137
67. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43:970-976
68. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM (2003) Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108:2141-2143
69. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ (2007) Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol 292:H736-H742
70. Ferreira AJ, Oliveira TL, Castro MC, Almeida AP, Castro CH, Caliari MV, Gava E, Kitten GT, Santos RA (2007) Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci 81:916-923
71. De Mello WC (2004) Angiotensin (1-7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. J Renin Angiotensin Aldosterone Syst 5:203-208
72. Ferreira AJ, Santos RA, Almeida AP (2001) Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 38:665-668
73. Ferreira AJ, Santos RA, Almeida AP (2002) Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. Braz J Med Biol Res 35:1083-1090
74. De Mello WC, Ferrario CM, Jessup JA (2007) Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst 8:74-80
75. Neves LA, Almeida AP, Khosla MC, Campagnole-Santos MJ, Santos RA (1997) Effect of angiotensin-(1-7) on reperfusion arrhythmias in isolated rat hearts. Braz J Med Biol Res 30:801-809
76. DelliPizzi A, Hilchey SD, Bell-Quilley CP (1994) Natriuretic action of angiotensin (1-7). Br J Pharmacol 111:1-3
77. Heller J, Kramer HJ, Maly J, Cervenka L, Horacek V (2000) Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney Blood Press Res 23:89-94
78. Vallon V, Heyne N, Richter K, Khosla MC, Fechter K (1998) [7-D-ALA]-Angiotensin 1-7 blocks renal actions of angiotensin 1-7 in the anesthetized rat. J Cardiovasc Pharmacol 32:164-167
79. Handa RK, Ferrario CM, Strandhoy JW (1996) Renal actions of angiotensin-(1-7) in vivo and in vitro studies. Am J Physiol 270:F141-F147
80. Burgelova M, Kramer HJ, Teplan V, Thumova M, Cervenka L (2005) Effects of angiotensin-(1-7) blockade on renal function in rats with enhanced intrarenal Ang II activity. Kidney Int 67:1453-1461
81. Chappell MC, Brosnihan KB, Diz DI, Ferrario CM (1989) Identification of angiotensin-(1-7) in rat brain: evidence for differential processing of angiotensin peptides. J Biol Chem 264:16518-16523
82. Campagnole-Santos MJ, Diz DI, Santos RAS, Khosla MC, Brosnihan KB, Ferrario CM (1989) Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol 257:H324-H329
83. Benter IF, Diz DI, Ferrario CM (1995) Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 26:1138-1144
84. Campagnole-Santos MJ, Heringer SB, Batista EN, Khosla MC, Santos RAS (1992) Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol 263:R89-R94
85. Oliveira DR, Santos RAS, Santos GFP, Khosla MC, Campagnole-Santos MJ (1996) Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension 27:1284-1290
86. Chaves GZ, Caligiorne SM, Santos RAS, Khosla MC, Campagnole-Santos MJ (2000) Modulation of the baroreflex control of heart rate by angiotensin-(1-7) at the nucleus tractus solitarii of normotensive and spontaneously hypertensive rats. J Hypertens 18:1841-1848
87. Diz DI, Westwood BM (2000) Deficiency of endogenous angiotensin-(1-7) in the nucleus tractus solitarii of (mREN2)27 transgenic rats may account for diminished baroreceptor reflex function. Hypertension 36:681
88. Fontes MA, Pinge MC, Naves V, Campagnole-Santos MJ, Lopes OU, Khosla MC, Santos RA (1997) Cardiovascular effects produced by microinjection of angiotensins and angiotensin antagonists into the ventrolateral medulla of freely moving rats. Brain Res 750:305-310
89. Potts PD, Horiuchi J, Coleman MJ, Dampney RA (2000) The cardiovascular effects of angiotensin-(1-7) in the rostral and caudal ventrolateral medulla of the rabbit. Brain Res 877:58-64
90. Potts PD, Allen AM, Horiuchi J, Dampney RA (2000) Does angiotensin II have a significant tonic action on cardiovascular neurons in the rostral and caudal VLM? Am J Physiol 279:R1392-R1402
91. Hellner K, Walther T, Schubert M, Albrecht D (2005) Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol Cell Neurosci 29:427-435
92. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28:104-108
93. Strawn WB, Ferrario CM, Tallant EA (1999) Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33:207-211
94. Loot AE, Roks AJM, Henning RH, Tio RA, Suurmeijer AHH, Boomsma F, vanGilst WH (2002) Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105:1548-1550
95. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH (2005) Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol 289:H2356-H2363
96. Wang LJ, He JG, Ma H, Cai YM, Liao XX, Zeng WT, Liu J, Wang LC (2005) Chronic administration of angiotensin-(1-7) attenuates pressure-overload left ventricular hypertrophy and fibrosis in rats. Di Yi Jun Yi Da Xue Xue Bao 25:481-487
97. Machado RD, Santos RA, Andrade SP (2000) Opposing actions of angiotensins on angiogenesis. Life Sci 66:67-76
98. Gallagher PE, Tallant EA (2004) Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25:2045-2052
99. Pantoja DS, Tallant AE, Gallagher PE (2004) Inhibition of human breast cancer cell growth by angiotensin-(1-7). Proc Am Assoc Cancer Res 45
100. Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE (2007) Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 67:2809-2815
101. Valdes G, Neves LA, Anton L, Corthorn J, Chacon C, Germain AM, Merrill DC, Ferrario CM, Sarao R, Penninger J, Brosnihan KB (2006) Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta 27:200-207
102. Merrill DC, Karoly M, Chen K, Ferrario CM, Brosnihan KB (2002) Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 18:239-245
103. Valdes G, Germain AM, Corthorn J, Berrios C, Foradori AC, Ferrario CM, Brosnihan KB (2001) Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine 16:117-122
104. Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chappell MC, Ferrario CM, Davis WP, Brosnihan KB (2007) Temporal-spatial expression of angiotensin-(1-7) and angiotensin converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol 239:R169-R177
105. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K (2006) Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 350:1026-1031
106. Jessup JA, Trask AJ, Chappell MC, Nagata S, Kato J, Kitamura K, Ferrario CM (2008) Localization of the novel angiotensin peptide, angiotensin-12 [Ang-(1-2)], in the heart and kidney of hypertensive and normotensive rats. Am J Physiol (in press)
107. Chappell MC, Westwood BM, Pendergrass KD, Jessup JA, Ferrario CM (2007)Distinct processing pathways for the novel peptide angiotensin-(1-12) in the serum and kidney of the hypertensive mRen2.Lewis Rat. Hypertension 50:e139
108. Trask AJ, Jessup JA, Chappell MC, Ferrario CM (2008) Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol (in press)
109. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370:221-229
110. Trask AJ, Ferrario CM (2007) Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 25:162-174